Paxlovid Offers No Benefit to the Middle-aged, Study Shows
Paxlovid, Pfizer’s oral antiviral drug to treat COVID-19, offers little or no benefit for adults between age 40 and 65, according to a large study in Israel.
Source: Drug Industry Daily
Paxlovid, Pfizer’s oral antiviral drug to treat COVID-19, offers little or no benefit for adults between age 40 and 65, according to a large study in Israel.
Source: Drug Industry Daily